EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical pharmacology of SGLT-2 inhibitors in heart failure

Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis, John Parissis

Expert Review of Clinical Pharmacology · 01.02.2023 · 16 (2) · 149-160

DOI: 10.1080/17512433.2023.2173574 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 02.02.2023. Verfasst von Maria Velliou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Medicine Department, Attikon University Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 86 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of oral antiglycemic agents that have emerged as a new therapeutic strategy for heart failure (HF) with reduced ejection fraction (HFrEF) and, potentially, for HF with preserved ejection fraction (HFpEF). AREAS COVERED: Ongoing efforts to clarify the exact mechanisms of action of SGLT2 inhibitors (SGLT2i) reveal that glycosuria and osmotic diuresis, resulting from the blockade of renal receptors, is not the sole pathophysiological mechanism. Nevertheless, the underlying mechanisms, accounting for their cardiovascular beneficial effects which have been clearly demonstrated in clinical trials, remain unclear. The aim of this review is to summarize the primary outcomes of large-scale studies regarding the use of SGLT2i in HF and provide an overview of the potential pathways involved in the SGLT2i-mediated cardioprotection. EXPERT OPINION: SGLT2i exhibit favorable pleiotropic effects, which extend beyond their primary indication as pharmaceutical agents intended for glycemic control. Given their unique pathophysiological profile, these agents have revolutionized the management of HF, while in the near future, it is possible that evolving research in the field may unfold further perspectives on their potential use in the treatment of other chronic conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureDiabetes Mellitus, Type 2HumansStroke Volume

Stichwörter der Autor:innen

DapagliflozinSGLT2 inhibitorsempagliflozinheart failuresotagliflozin

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Emergency Medicine Department, Attikon University Hospital, Athens, Greece.
  • Department of Occupational Therapy, University of Western Macedonia, Ptolemaida, Greece.
  • Heart Failure Clinic, Attikon University Hospital, Athens, Greece.

Zitieren

APA

Velliou, M., Polyzogopoulou, E., Ventoulis, I., & Parissis, J. (2023). Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology, 16(2), 149-160. https://doi.org/10.1080/17512433.2023.2173574

Vancouver

Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J. Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology. 2023;16(2):149-160. doi:10.1080/17512433.2023.2173574

BibTeX
@article{Velliou2023,
  author = {Velliou, Maria and Polyzogopoulou, Effie and Ventoulis, Ioannis and Parissis, John},
  title = {Clinical pharmacology of SGLT-2 inhibitors in heart failure},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {149--160},
  doi = {10.1080/17512433.2023.2173574}
}
Kostenlos starten →